Knight Therapeutics Inc.

TSX:GUD Stock Report

Market Cap: CA$534.3m

Knight Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSX:GUD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Nov 24BuyCA$513,709G2s2 Capital Inc.Company100,000CA$5.16
11 Nov 24BuyCA$103,000Samira SakhiaIndividual20,000CA$5.15
16 Sep 24SellCA$1,839,000G2s2 Capital Inc.Company300,000CA$6.13
05 Jun 24BuyCA$29,000Jonathan GoodmanIndividual5,000CA$5.80
29 May 24SellCA$147,883Robert LandeIndividual25,000CA$5.93
23 May 24SellCA$118,710Robert LandeIndividual20,000CA$5.94
09 May 24SellCA$440,892G2s2 Capital Inc.Company74,100CA$5.95
07 May 24SellCA$89,250G2s2 Capital Inc.Company15,000CA$5.95
11 Apr 24SellCA$64,855G2s2 Capital Inc.Company10,900CA$5.95
03 Apr 24BuyCA$49,780G2s2 Capital Inc.Company9,500CA$5.24
01 Apr 24BuyCA$32,550G2s2 Capital Inc.Company6,200CA$5.25
25 Mar 24BuyCA$1,881,142G2s2 Capital Inc.Company358,300CA$5.26
12 Mar 24BuyCA$664,650G2s2 Capital Inc.Company126,600CA$5.25
31 Jan 24BuyCA$786,391G2s2 Capital Inc.Company147,000CA$5.35
22 Jan 24SellCA$162,150G2s2 Capital Inc.Company28,200CA$5.75
19 Jan 24SellCA$523,250G2s2 Capital Inc.Company91,000CA$5.75

Insider Trading Volume

Insider Buying: GUD insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GUD?
Owner TypeNumber of SharesOwnership Percentage
Private Companies12,973,50512.9%
Individual Insiders22,605,22622.4%
Institutions24,153,67424%
General Public41,070,36040.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 58.69% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
21.6%
Jonathan Goodman
21,765,983CA$115.4m0.01%no data
12.9%
Medici Strategic Portfolio Management Inc
12,973,505CA$68.8m0%no data
12.4%
G2s2 Capital Inc.
12,466,200CA$66.1m0.81%10.42%
2.84%
Industrielle Alliance, Gestion de placements inc.
2,859,009CA$15.2m0%0.13%
2.56%
Dimensional Fund Advisors LP
2,580,140CA$13.7m-0.71%no data
1.87%
QV Investors Inc.
1,888,716CA$10.0m0%0.34%
0.85%
COTE 100, Inc.
852,750CA$4.5m0%2.26%
0.69%
FMR LLC
694,028CA$3.7m0%no data
0.33%
Artisan Partners Limited Partnership
333,951CA$1.8m16.5%no data
0.32%
North Growth Management Ltd.
327,000CA$1.7m0%0.21%
0.28%
Samira Sakhia
281,911CA$1.5m9.15%no data
0.25%
Bessemer Investment Management LLC
253,979CA$1.3m-38.2%no data
0.24%
Robert Lande
243,178CA$1.3m0%no data
0.24%
Royce & Associates, LP
237,000CA$1.3m0%0.01%
0.22%
Tredje AP-fonden
221,189CA$1.2m0%no data
0.19%
CI Investment Consulting
195,379CA$1.0m0%0.21%
0.16%
AGF Management Limited
161,821CA$857.6k0%no data
0.16%
Amal Khouri
160,193CA$849.0k1.93%no data
0.12%
KLP Kapitalforvaltning AS
120,200CA$637.0k0%no data
0.1%
Hillsdale Investment Management Inc.
105,567CA$559.5k0%0.02%
0.099%
McElvaine Investment Management Ltd.
100,000CA$530.0k0%2.43%
0.099%
Ampega Investment GmbH
100,000CA$530.0k0%0.01%
0.097%
State Street Global Advisors, Inc.
97,549CA$517.0k-19.5%no data
0.079%
Brandes Investment Partners, LP
79,374CA$420.7k0%no data
0.063%
BlackRock, Inc.
63,044CA$334.1k-82.1%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 01:36
End of Day Share Price 2025/01/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Knight Therapeutics Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David KideckelBeacon Securities Limited
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity